Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748440 | 0.94 | ADRB2 (0.44) | ADRB2EPHX2ADRB1ADRB3 | |
| SCHEMBL2748419 | 0.89 | EPHX2 (0.46) | ADRB2EPHX2ADRB3 | |
| SCHEMBL2748974 | 0.86 | ADRB2 (0.35) | ADRB2EPHX2ADRB1ADRB3MEN1 | |
| SCHEMBL2749295 | 0.85 | ADRB2 (0.61) | ADRB2EPHX2ADRB1ADRB3 | |
| SCHEMBL2748442 | 0.83 | EPHX2 (0.39) | ADRB2EPHX2ADRB1ADRB3 | |
| SCHEMBL2795663 | 0.83 | ADRB2 (0.45) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL2795662 | 0.83 | ADRB2 (0.45) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL774598 | 0.81 | ADRB2 (0.57) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL2748567 | 0.80 | EPHX2 (0.42) | ADRB2EPHX2ADRB1ADRB3 | |
| SCHEMBL4144944 | 0.79 | ADRB2 (0.48) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
| EP-2212276-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068177-A1 | DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885EPHX2 598/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.